|
| 37195235 | A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. | Clin Cancer Res | 2023 |
| 36716289 | Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis. | | 2023 |
| 36827742 | Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. | | 2023 |
| 37467106 | High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer. | Cell Rep | 2023 |
| 34645649 | Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER/HER2 Breast Cancer. | Clinical Cancer Research | 2022 |
| 36001024 | Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. | Cancer Discov | 2022 |
| 35860837 | Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. | Therapeutic Advances in Medical Oncology | 2022 |
| 36619972 | Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. | iScience | 2022 |
| 34470810 | Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. | Clin Cancer Res | 2021 |
| 33536276 | Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. | Clin Cancer Res | 2021 |
| 34045483 | Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. | npj Breast Cancer | 2021 |
| 34515904 | Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer. | Breast Cancer Research and Treatment | 2021 |
| 31037288 | HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. | J Natl Cancer Inst | 2020 |
| 32000054 | HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. | | 2020 |
| 31662331 | TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. | Clin Cancer Res | 2020 |
| 31917424 | Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. | JAMA Oncol | 2020 |
| 31653641 | Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. | Clin Cancer Res | 2020 |
| 32675852 | DE-ESCALATING TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCER. | Transactions of the American Clinical and Climatological Association | 2020 |
| 30903140 | A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. | Ann Oncol | 2019 |
| 30523750 | Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. | J Clin Oncol | 2019 |
| 30928413 | Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study. | Clin Breast Cancer | 2019 |
| 31420371 | Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. | Mol Cancer Res | 2019 |
| 31218477 | Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. | Breast Cancer Research and Treatment | 2019 |
| 31017314 | Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. | Histopathology | 2019 |
| 29574636 | GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. | Breast Cancer Research and Treatment | 2018 |
| 29045519 | Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. | Ann Oncol | 2018 |
| 30511015 | Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. | NPJ Breast Cancer | 2018 |
| 30106636 | First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Tr | Journal of Clinical Oncology | 2018 |
| 29128193 | Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. | Clin Breast Cancer | 2018 |
| 29592880 | Trastuzumab-Resistant HER2<sup>+</sup> Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition. | Mol Cancer Ther | 2018 |
| 29110152 | Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. | Breast Cancer Res Treat | 2018 |
| 29733336 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. | Ann Oncol | 2018 |
| 29578538 | Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. | Nat Med | 2018 |
| 28196254 | Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. | JAMA - Journal of the American Medical Association | 2017 |
| 28730340 | CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. | Breast Cancer Res Treat | 2017 |
| 28729021 | ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). | Journal of Thoracic Oncology | 2017 |
| 28687441 | De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. | Breast | 2017 |
| 28487443 | HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast Cancer. | Clin Cancer Res | 2017 |
| 28838210 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. | Ann Oncol | 2017 |
| 27671678 | Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. | Cancer Res | 2016 |
| 28721378 | Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. | NPJ Breast Cancer | 2016 |
| 27393618 | Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. | Breast Cancer Res Treat | 2016 |
| 26965145 | Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. | Mol Cancer Res | 2016 |
| 26921331 | Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. | Cancer Res | 2016 |
| 27791031 | FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. | Proc Natl Acad Sci U S A | 2016 |
| 25208879 | Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. | Clin Cancer Res | 2015 |
| 25587647 | Targeting HER2 for the treatment of breast cancer. | Annual Review of Medicine | 2015 |
| 25698062 | An international study to increase concordance in Ki67 scoring. | Mod Pathol | 2015 |
| 25537159 | A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer. | Clinical Breast Cancer | 2015 |
| 25572662 | Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. | Breast Cancer Res | 2015 |